Related Experiment Video
Updated: Oct 2, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
Published on: May 7, 2020
Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose)
Uwe Koedel1, Frank Winkler, Barbara Angele
1Department of Neurology, Klinikum Grosshadern, Munich, Germany.
Abstract:
The present study assessed the role of PARP [poly(adenosine diphosphate-ribose) polymerase] activation in experimental pneumococcal meningitis. Mice with a targeted disruption of the PARP 1 gene were protected against meningitis-associated central nervous system complications including blood-brain barrier breaching and increase in intracranial pressure. This beneficial effect was paralleled by a significant reduction in meningeal inflammation, as evidenced by significantly lower cerebrospinal fluid leukocyte counts and interleukin-1beta, -6, and tumor necrosis factor-alpha concentrations in the brain (compared with infected wild-type mice). The reduction in inflammation and central nervous system complications was associated with an improved clinical status of infected, PARP 1-deficient mice. A similar protective effect was achieved by PARP inhibition using 3-aminobenzamide, the pharmacologic efficacy of which was confirmed by a marked attenuation of meningitis-induced poly(ADP)ribose formation. When the rat brain-derived endothelial cell line GP8.3 was cocultured with macrophages, exposure to pneumococci induced endothelial cell death and was paralleled by PARP activation and a reduction in the oxidized form of cellular nicotinamide adenine dinucleotide content. Treatment with 3-aminobenzamide significantly attenuated cellular nicotinamide adenine dinucleotide depletion and pneumococci-induced cytotoxicity. Thus, PARP activation seems to play a crucial role in the development of meningitis-associated central nervous system complications and pneumococci-induced endothelial injury. Inhibitors of PARP activation could provide a potential therapy of acute bacterial meningitis.
Insights
Poly(adenosine diphosphate-ribose) polymerase (PARP) activation contributes to brain injury in experimental pneumococcal meningitis. Inhibiting PARP protects against central nervous system complications and reduces inflammation, suggesting PARP inhibitors as potential therapies.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Pneumococcal meningitis can cause severe central nervous system (CNS) complications.
- The role of poly(adenosine diphosphate-ribose) polymerase (PARP) activation in meningitis pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the role of PARP activation in experimental pneumococcal meningitis.
- To evaluate the therapeutic potential of PARP inhibition.
Main Methods:
- Utilized PARP 1 gene-deficient mice and wild-type mice infected with Streptococcus pneumoniae.
- Administered the PARP inhibitor 3-aminobenzamide.
- Assessed CNS complications, including blood-brain barrier integrity and intracranial pressure.
- Measured inflammatory markers (cytokines, leukocytes) in cerebrospinal fluid and brain tissue.
- Examined PARP activation and nicotinamide adenine dinucleotide levels in endothelial cells exposed to pneumococci.
Main Results:
- PARP 1 deficiency protected mice from meningitis-associated CNS complications and inflammation.
- PARP inhibition with 3-aminobenzamide conferred similar protection, reducing inflammation and improving clinical outcomes.
- Pneumococcal challenge induced PARP activation and endothelial cell death, which was attenuated by 3-aminobenzamide.
- PARP activation correlated with reduced cellular nicotinamide adenine dinucleotide levels and increased cytotoxicity.
Conclusions:
- PARP activation plays a critical role in the pathogenesis of pneumococcal meningitis and associated CNS injury.
- PARP inhibition demonstrates therapeutic potential for treating bacterial meningitis.
- Targeting PARP activation may mitigate pneumococci-induced endothelial damage.
Related Concept Videos
Bacterial Meningitis II: Pathophysiology
Bacterial Meningitis
Encephalitis ll: Pathophysiology
Bacterial Meningitis I: Introduction
Viral Meningitis
Encephalitis l: Introduction
